RayKnowChina Research Map
Shortlist

GuiyangGuizhou Medical University

Affiliated Hospital of Guizhou Medical University

贵州医科大学附属医院

Listed for 25 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Hospital of Guizhou Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌12 papers led
  2. Hepatocellular carcinoma肝细胞癌38 papers led
  3. Stomach cancer胃癌17 papers led
  4. Lung cancer肺癌31 papers led2 open trials led
  5. Pancreatic cancer胰腺癌22 papers led
  6. Breast cancer乳腺癌29 papers led2 open trials led
  7. Glioma胶质瘤21 papers led
  8. Retinoblastoma视网膜母细胞瘤0 papers led
  9. Osteosarcoma骨肉瘤8 papers led
  10. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  11. Neuroblastoma神经母细胞瘤4 papers led
  12. Ewing sarcoma尤文肉瘤1 paper led
  13. Multiple myeloma多发性骨髓瘤8 papers led
  14. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  15. Lymphoma淋巴瘤7 papers led
  16. Beta thalassaemiaβ 地中海贫血1 paper led
  17. Haemophilia A血友病 A0 papers led
  18. Myasthenia gravis重症肌无力3 papers led
  19. Coronary heart disease冠心病7 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  22. Behçet disease白塞病1 paper led
  23. Alport syndromeAlport 综合征1 paper led
  24. IgA nephropathyIgA 肾病0 papers led
  25. Hirschsprung disease先天性巨结肠1 paper led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Chordoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 12 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 0020232024: 5520242025: 222025

2 hospitals in Guiyang for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Posted
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  2. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Posted
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersMedical oncologyENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led12
  1. High-dose radiation induces dendritic cells maturation by promoting immunogenic cell death in nasopharyngeal carcinoma.2025Frontiers in immunologyFree full text
  2. High-dose ionizing radiation-induced ferroptosis leads to radiotherapy sensitization of nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  3. Research trends and hotspots in surgical treatment of recurrent nasopharyngeal carcinoma: A bibliometric analysis from 2000 to 2023.2024Asian journal of surgery
  4. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.2024BMC immunologyFree full text
  5. Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.2024Oral oncologyRCT
  6. The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-β1/Smads/Snail1 axis.2024Oral oncology
  7. Immunohistochemical Expression and Clinical Significance of WWP1 Protein in Nasopharyngeal Cancer.2024The journal of histochemistry and cytochemistry : official journal of the Histochemistry SocietyFree full text
  8. Long non-coding RNA RGMB-AS1 represses nasopharyngeal carcinoma progression via binding to forkhead box A1.2022BioengineeredFree full text
  9. Circadian clock gene BMAL1 inhibits the proliferation and tumor-formation ability of nasopharyngeal carcinoma cells and increases the sensitivity of radiotherapy.2022Chronobiology international
  10. EPHB2 as a recurrence-related gene and a prognostic indicator in nasopharyngeal carcinoma: A bioinformatics screening and immunohistochemistry verification.2022Histology and histopathology
  11. Overexpression of KITLG predicts unfavorable clinical outcomes and promotes lymph node metastasis via the JAK/STAT pathway in nasopharyngeal carcinoma.2022Laboratory investigation; a journal of technical methods and pathology
  12. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma.2021Journal of cellular and molecular medicineFree full text
Chinese-language papers (not in the count)2
  1. [Expression of pepsin in nasopharyngeal carcinoma and its correlation with quality of life after radiotherapy].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [The expression of clock gene CLOCK and its clinical significance in nasopharyngeal carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status7
  1. Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical StudyStatus unknownNCT02187315Lead (inferred)Phase 2Start 2014-05
  2. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  3. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  5. Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaActive, not recruitingNCT05211232Study sitePhase 3Start 2022-06
  6. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  7. Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal CarcinomaStatus unknownNCT03321539Study sitePhase 3Start 2017-10
More papers found outside PubMed (not counted)25
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  2. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  3. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  4. Chronomodulated chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A phase II randomized controlled trial2024Radiation Medicine and Protectionarticle
  5. Correlation of the biological clock gene PER1 with ferroptosis in nasopharyngeal carcinoma2024Biological Rhythm Researcharticle
  6. Expression of bromodomain-containing 4 in nasopharyngeal carcinoma: Clinicopathology, prognosis, immunity, and regulatory networks2024Journal of Laboratory Physiciansarticle
  7. Influence of intensity-modulated radiation therapy on long-term survival and late injury in patients with nasopharyngeal carcinoma after induction chemotherapy.2024Journal of Clinical Oncologyconference-abstract
  8. Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in patients with locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: A retrospective study with a 5-2024Journal of Clinical Oncologyconference-abstract
  9. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  10. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncologyconference-abstract
  11. The Correlation Study of Circadian Clock Gene Bmal1 on Growth Inhibition and Radiosensitivity in Subcutaneous Xenograft of Human Nasopharyngeal Carcinoma CNE1 in Nude Mice2024International Journal of Radiation Oncology*Biology*Physicsarticle
  12. The circadian clock gene BMAL1 increases radiosensitivity in nasopharyngeal carcinoma cell CNE22024Journal of Radiation Research and Applied Sciencesarticle
  13. The role and mechanism of circadian clock gene BMAL1 in the proliferation and metastasis of nasopharyngeal carcinoma by inhibition TGF-β1/Smads pathway.2024Journal of Clinical Oncologyconference-abstract
  14. Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomiz2024Journal of Clinical Oncologyconference-abstract
  15. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.2023Journal of Clinical Oncologyconference-abstract
  16. Effects of biological clock gene BMAL1 and hypoxia-inducible factor HIF-1α on proliferation, migration and radiotherapy sensitivity of nasopharyngeal carcinoma cells HONE12023Holistic Integrative Oncologyarticle
  17. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  18. Long-term follow-up results of the effects of chronotherapy and conventional chemotherapy combined with intensity modulated radiotherapy on dendritic cells and lymphocyte subsets in nasopharyngeal carcinoma.2022Journal of Clinical Oncologyconference-abstract
  19. TPF Induction Chemotherapy vs. PF Adjuvant Chemotherapy plus Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicenter, Randomized Controlled, III Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  20. TPF induction chemotherapy versus PF adjuvant chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled, III trial.2022Journal of Clinical Oncologyconference-abstract
  21. Associated with Immune Function, miR-150-5p is a Favorable Biomarker for Head and Neck Cancer Patients2021Research Squarepreprint
  22. Comparative Analysis of Clinical Results of Compared With TPF Induction of Chemotherapy and PF Adjuvant Chemotherapy Combined With Cisplatin Radiochemotherapy for Locally Advanced Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  23. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  24. The Correlation Study of Circadian Clock Gene BMAL1 Regulates the Biological Behavior of Human Nasopharyngeal Carcinoma Cell After Radiotherapy2021International Journal of Radiation Oncology*Biology*Physicsarticle
  25. We Hypothesize That BMAL1 Has a Positive Regulatory Effect on the Radiosensitivity of Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 38 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
38
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 9920222023: 111120232024: 8820242025: 882025

1 hospital in Guiyang for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePediatricsMedical oncology

Over half of these papers are lab or animal studies.

Papers it led38
  1. Three-dimensional multimodal imaging for predicting early recurrence of hepatocellular carcinoma after surgical resection.2026Journal of advanced researchFree full text
  2. Identification and Validation of Basement Membrane Related LncRNA Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma.2025Biochemical geneticsFree full text
  3. Kindlin-1 promotes mitophagy by inhibiting PINK1 degradation to enhance hepatocellular carcinoma progression and modulates sensitivity to donafenib.2025Cellular signalling
  4. YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression.2025Clinical and experimental medicineFree full text
  5. Predicting hepatocellular carcinoma response to TACE: A machine learning study based on 2.5D CT imaging and deep features analysis.2025European journal of radiology
  6. IRX5 Promoted SREBP1-Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma.2025Journal of cellular and molecular medicineFree full text
  7. Glutamine reprogramming affects the tumor microenvironment and immune response in hepatocellular carcinoma.2025Molecular biology reports
  8. IL27RA promotes the proliferation and metastasis of hepatocellular carcinoma cells by regulating TGFβR1.2025Scientific reportsFree full text
  9. To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma.2025Scientific reportsFree full text
  10. PPIH acts as a potential predictive biomarker for patients with common solid tumors.2024BMC cancerFree full text
  11. Transcriptomic and genomic characteristics of intrahepatic metastases of primary liver cancer.2024BMC cancerFree full text
  12. m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma.2024BMC cancerFree full text
  13. The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.2024Cell cycle (Georgetown, Tex.)Free full text
  14. PRMT1-mediated methylation of ME2 promotes hepatocellular carcinoma growth by inhibiting ubiquitination.2024Cell death & diseaseFree full text
  15. Glycyrrhizic acid attenuates the malignant biological properties of nonalcoholic fatty liver disease-related hepatocellular carcinoma.2024Environmental toxicology
  16. Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma.2024Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
  17. MIA3 promotes the degradation of GSH (glutathione) by binding to CHAC1, thereby promoting the progression of hepatocellular carcinoma.2024Molecular and cellular biochemistryFree full text
  18. Apoprotein E methylation is correlated with immune microenvironment in hepatocellular carcinoma.2023Acta oncologica (Stockholm, Sweden)
  19. PPIH gene regulation system and its prognostic significance in hepatocellular carcinoma: a comprehensive analysis.2023AgingFree full text
  20. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.2023BMC cancerFree full text
  21. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway.2023Biochemical pharmacology
  22. TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC.2023Biology directFree full text
  23. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.2023Clinical and experimental medicineFree full text
  24. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma.2023Journal of cellular and molecular medicineFree full text
  25. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.2023Journal of ethnopharmacology
  26. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway.2023Medical oncology (Northwood, London, England)
  27. Silencing of peroxiredoxin 2 suppresses proliferation and Wnt/β-catenin pathway, and induces senescence in hepatocellular carcinoma.2023Oncology researchFree full text
  28. Prediction of 3-year recurrence rate of hepatocellular carcinoma after resection based on contrast-enhanced CT: a single-centre study.2023The British journal of radiologyFree full text
  29. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway.2022AgingFree full text
  30. Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis.2022BioMed research internationalFree full text
  31. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.2022BioengineeredFree full text
  32. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway.2022Cell proliferationFree full text
  33. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.2022CellsFree full text
  34. Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37.2022Experimental cell research
  35. WD repeat domain 48 promotes hepatocellular carcinoma progression by stabilizing c-Myc.2022Journal of cellular and molecular medicineFree full text
  36. Aidi injection altered the activity of CYP2D4, CYP1A2, CYP2C19, CYP3A2, CYP2E1 and CYP2C11 in normal and diethylnitrosamine-induced hepatocellular carcinoma in rats.2022Journal of ethnopharmacology
  37. circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway.2022Journal of immunology researchFree full text
  38. CircC16orf62 promotes hepatocellular carcinoma progression through the miR-138-5p/PTK2/AKT axis.2021Cell death & diseaseFree full text
All its trials on ClinicalTrials.gov, any status2
  1. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  2. Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT02956772Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 3320232024: 5520242025: 662025

1 hospital in Guiyang for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsEarly detection & endoscopy
Departments in papersPathology / laboratory medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led17
  1. Juglone targets MMP-1 to inhibit gastric cancer progression.2025Biochemical pharmacology
  2. Case report: Local and systemic combination therapy: endoscopic injection of an oncolytic virus with PD-1 inhibitor for an elderly patient with advanced gastrointestinal cancer.2025Frontiers in immunologyFree full text
  3. Liquid-liquid phase separation in gastric cancer: identifying novel biomarkers and therapeutic targets through gene signature analysis.2025Frontiers in immunologyFree full text
  4. Identification of a tumor microenvironment-related gene signature for predicting prognosis in patients with gastric cancer.2025MedicineFree full text
  5. Super-enhancer-associated LINC00963 promotes metastasis of gastric cancer through epithelial-mesenchymal transition.2025PloS oneFree full text
  6. Study on the regulation of gastric cancer cell apoptosis by LACTB through mitochondrial autophagy pathway.2025Scientific reportsFree full text
  7. PPIH acts as a potential predictive biomarker for patients with common solid tumors.2024BMC cancerFree full text
  8. Short term efficacy and safety of PD-1 inhibitor and apatinib plus S-1 and oxaliplatin as neoadjuvant chemotherapy for patients with locally advanced gastric cancer.2024MedicineFree full text
  9. Long-term survival in a patient with multiple metastatic gastric cancer treated with PTX plus emvolimab and disitamab vedotin: case report and treatment experience: A case report.2024MedicineFree full text
  10. Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway.2024Scientific reportsFree full text
  11. Gastric Cancer Signaling Pathways and Therapeutic Applications.2024Technology in cancer research & treatmentFree full text
  12. A potential therapeutic approach for gastric cancer: inhibition of LACTB transcript 1.2023AgingFree full text
  13. CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis.2023AgingFree full text
  14. Super-enhancer-associated EEPD1 facilitates EMT-mediated metastasis by regulating the PI3K/AKT/mTOR pathway in gastric cancer.2023Biochemical and biophysical research communications
  15. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.2022Canadian journal of gastroenterology & hepatologyFree full text
  16. Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis.2022Journal of translational medicineFree full text
  17. SNHG16 lncRNAs are overexpressed and may be oncogenic in human gastric cancer by regulating cell cycle progression.2022Neoplasma
Chinese-language papers (not in the count)1
  1. [Application of posterior gastric mesentery in laparoscopic gastric surgery].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status4
  1. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  3. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  4. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 31 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
31
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 7720232024: 6620242025: 882025

2 hospitals in Guiyang for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07905937

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  2. Recruiting
    Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
    Phase
    N/A
    Started
    2021-04
    Posted
    Registry
    NCT05150145

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  3. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineNephrologySurgery (general/hepatobiliary/pancreatic)
Papers it led31
  1. Selective Activation of Conditionally Replicating Influenza A Virus in Pulmonary Tumors for Enhanced Oncolytic Efficacy and Systemic Safety.2026Advanced healthcare materials
  2. Development and validation of a transformer-based deep learning model for predicting distant metastasis in non-small cell lung cancer using 18FDG PET/CT images.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. ZNF460 enhances HADHB level by activating its transcription to promote the progression and pulmonary invasion of cutaneous T cell lymphoma.2025Archives of biochemistry and biophysics
  4. Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study.2025BMC cancerFree full text
  5. Cancer-associated fibroblasts secreting IL-6 inhibit the cisplatin and docetaxel killing effect in lung squamous cell carcinoma.2025Biochimica et biophysica acta. Molecular cell research
  6. Failure patterns analysis of three-dimensional radiotherapy for stage IV non-small cell lung cancer primary tumours.2025Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  7. Development and validation of an interpretable machine learning model for predicting progression-free survival after immunotherapy in patients with non-small cell lung cancer: a multicenter study.2025Frontiers in immunologyFree full text
  8. Study on PD-1 inhibitor combined with recombinant human endostatin and chemotherapy followed by IMRT in the treatment of advanced NSCLC.2025MedicineFree full text
  9. Analysis of the prognostic and immune role of MCM6 in pan-cancer and experimental validation in lung adenocarcinoma cells.2025Scientific reportsFree full text
  10. Pretreatment CT-Based Machine Learning Radiomics Model Predicts Response in Inoperable Stage III NSCLC Treated with Concurrent Radiochemotherapy Plus PD-1 Inhibitors.2025Technology in cancer research & treatmentFree full text
  11. Deep Learning Based on Computed Tomography Predicts Response to Chemoimmunotherapy in Lung Squamous Cell Carcinoma.2024Aging and diseaseFree full text
  12. Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs.2024BMC cancerFree full text
  13. Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non-small cell lung cancer.2024Cancer medicineFree full text
  14. Quality control of postoperative radiotherapy for non-small cell lung cancer: A study of mediastinal shift.2024Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  15. Deep learning to estimate response of concurrent chemoradiotherapy in non-small-cell lung carcinoma.2024Journal of translational medicineFree full text
  16. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.2024Journal of translational medicineFree full text
  17. The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  18. ARNTL2 upregulation of ACOT7 promotes NSCLC cell proliferation through inhibition of apoptosis and ferroptosis.2023BMC molecular and cell biologyFree full text
  19. N6-methyladenosine-regulated ADIRF impairs lung adenocarcinoma metastasis and serves as a potential prognostic biomarker.2023Cancer biology & therapyFree full text
  20. Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.2023Cancer medicineFree full text
  21. Circ_0006324 regulates cell proliferation, cell-cycle progression, apoptosis, and glycolysis of non-small cell lung cancer cells through miR-496/TRIM59 axis.2023Journal of biochemical and molecular toxicology
  22. MEN1 is a regulator of alternative splicing and prevents R-loop-induced genome instability through suppression of RNA polymerase II elongation.2023Nucleic acids researchFree full text
  23. Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL3.2023Pulmonary pharmacology & therapeutics
  24. TRPV3 promotes the angiogenesis through HIF-1α-VEGF signaling pathway in A549 cells.2022Acta histochemica
  25. Letter to the editor concerning 'Minimally invasive surgery (MIS) versus thoracotomy for resectable stage II and III non-small-cell lung cancers: a systematic review and meta-analysis' by Shen et al.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  26. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade.2022Frontiers in immunologyFree full text
  27. CircMIIP Contributes to Non-Small Cell Lung Cancer Progression by Binding miR-766-5p to Upregulate FAM83A Expression.2022Lung
  28. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.2022Technology in cancer research & treatmentFree full text
  29. A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.2021Frontiers in immunologyFree full text
  30. Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study.2021Future oncology (London, England)
  31. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).2021Oncology reportsFree full text
Chinese-language papers (not in the count)1
  1. [COL11A1 regulates PI3K/Akt/GSK-3β pathway and promotes human lung adenocarcinoma primary cell migration and invasion].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status13
  1. Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain InjuryRecruitingNCT07905937Lead (inferred)Start 2026-06
  2. Radiotherapy or Observation of Liver Metastases in Small Cell Lung CancerRecruitingNCT05150145Lead (inferred)N/AStart 2021-04
  3. Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical StudyStatus unknownNCT06014450Lead (inferred)N/AStart 2023-09
  4. A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLCStatus unknownNCT04654520Lead (inferred)N/AStart 2020-12
  5. Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung CancerStatus unknownNCT03613597Lead (inferred)Phase 2Start 2018-06
  6. A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLCStatus unknownNCT03987087Lead (inferred)Phase 2Start 2018-09
  7. Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung CancerStatus unknownNCT03613753Lead (inferred)Phase 2Start 2018-06
  8. IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung CancerStatus unknownNCT03258671Lead (inferred)N/AStart 2017-10
  9. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  10. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  11. SBRT With S1 Combined With Endostar in the Treatment of Lung CancerStatus unknownNCT04274270Study siteN/AStart 2020-04
  12. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Study sitePhase 3Start 2018-07
  13. Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21Status unknownNCT01714908Study sitePhase 2Start 2012-12

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 22 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
22
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 8820222023: 3320232024: 4420242025: 772025

3 hospitals in Guiyang for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06799637

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Kunming, Luoyang, Shanghai, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led22
  1. EUS-FNA with ROSE for pancreatic solid lesions: a single-center experience.2025BMC gastroenterologyFree full text
  2. PRRX2 Regulates GLI2 to Promote Proliferation, Invasion, and Metastasis by Inhibiting Senescence via Hedgehog Signaling.2025Cancer scienceFree full text
  3. ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer.2025Cell death & diseaseFree full text
  4. CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance.2025Cell death & diseaseFree full text
  5. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  6. Sciellin inhibits senescence and promotes pancreatic cancer progress by activating the notch signaling pathway.2025Scientific reportsFree full text
  7. Impact of personlized exercise prescription on muscle mass, physical function, and quality of life in postoperative pancreatic cancer patients undergoing da Vinci robotic surgery: a randomized controlled trial protocol.2025TrialsFree full text
  8. HOXC4 promotes proliferation of pancreatic cancer cells by increasing LDHA-mediated glycolysis.2024AgingFree full text
  9. A study on the role of Taxifolin in inducing apoptosis of pancreatic cancer cells: screening results using weighted gene co-expression network analysis.2024AgingFree full text
  10. Transcription factor KLF9 inhibits the proliferation, invasion, and migration of pancreatic cancer cells by repressing KIAA1522.2024Asia-Pacific journal of clinical oncology
  11. Suppression of hypoxia-induced CAV1 autophagic degradation enhances nanoalbumin-paclitaxel transcytosis and improves therapeutic activity in pancreatic cancer.2024European journal of pharmacology
  12. NAP1L5 facilitates pancreatic ductal adenocarcinoma progression via TRIM29-mediated ubiquitination of PHLPP1.2023Biochemical pharmacology
  13. FOXQ1 promotes pancreatic cancer cell proliferation, tumor stemness, invasion and metastasis through regulation of LDHA-mediated aerobic glycolysis.2023Cell death & diseaseFree full text
  14. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway.2023Medical oncology (Northwood, London, England)
  15. High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma.2022BMC cancerFree full text
  16. The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer.2022BioMed research internationalFree full text
  17. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis.2022Cancer letters
  18. RHBDL2 promotes the proliferation, migration, and invasion of pancreatic cancer by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling pathway.2022Cell death & diseaseFree full text
  19. FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis.2022Cell death & diseaseFree full text
  20. Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis.2022Cell death & diseaseFree full text
  21. MICAL1 facilitates pancreatic cancer proliferation, migration, and invasion by activating WNT/β-catenin pathway.2022Journal of translational medicineFree full text
  22. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.2022Medical oncology (Northwood, London, England)
All its trials on ClinicalTrials.gov, any status3
  1. A Comparative Clinical Research on Single Roux-en-Y and Traditional Roux-en-Y of Pancreaticojejunostomy-choledochojejunostomy For Treatment of Obstruction of Pancreatic Duct and Bile DuctStatus unknownNCT01926717Lead (inferred)Start 2010-12
  2. Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsRecruitingNCT06799637Study sitePhase 1/Phase 2Start 2023-12
  3. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 29 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
29
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 8820242025: 15152025

2 hospitals in Guiyang for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07739485

    Age 18 years to 70 years; women only (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  2. Recruiting
    Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07739511

    Age 18 years to 70 years; women only (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  3. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  4. Recruiting
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06889688

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan

  5. Recruiting
    Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07095023

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou

  6. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineNeurosurgeryClinical trials / research unit

Over half of these papers are lab or animal studies.

Papers it led29
  1. Comprehensive safety assessment of ribociclib: A real-world analysis using the FDA Adverse Event Reporting System (FAERS) database.2026British journal of clinical pharmacology
  2. Potential regulatory role of the m 6A-lncRNA axis in breast cancer: molecular mechanisms and therapeutic implications.2025Acta biochimica et biophysica SinicaFree full text
  3. Integrating RNA-seq and scRNA-seq to explore the prognostic features and immune landscape of exosome-related genes in breast cancer metastasis.2025Annals of medicineFree full text
  4. Repair of Radiation Ulcers After Breast Cancer Surgery With Simple Local Random Flaps.2025Annals of plastic surgery
  5. STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα.2025BiomoleculesFree full text
  6. Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl-2/Bax Pathway.2025Cancer medicineFree full text
  7. Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression.2025Cancer treatment reviews
  8. Multiomics analysis and prognostic modeling reveal the molecular features and potential therapeutic targets of breast cancer brain metastasis.2025Clinical and experimental medicineFree full text
  9. MZB1-Driven Endoplasmic reticulum stress model as a predictor of breast cancer progression and survival.2025Functional & integrative genomicsFree full text
  10. Dextran-engineered Cu-MOF nanozyme with multi-enzyme mimetic cascade for cuproptosis-enhanced synergistic therapy in triple-negative breast cancer.2025International journal of biological macromolecules
  11. MRO/HNRNPU/CCL5 feedback loop amplifies M2 macrophage and breast cancer cell crosstalk to drive progression.2025Journal of translational medicineFree full text
  12. Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics.2025Medical oncology (Northwood, London, England)
  13. Preferences for breast cancer screening: Results of a discrete choice experiment.2025Public health
  14. Effect of miR-6767-5p on breast cancer cell phenotype and its regulatory mechanism.2025Scientific reportsFree full text
  15. Oncofertility Barriers in Nurses Caring for Women with Breast Cancer.2025Scientific reportsFree full text
  16. Validation of the Oncofertility Support Scale derived from the Fertility Information Support scale among young adult women with breast cancer.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  17. Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry.2024AgingFree full text
  18. SCGB2A2 as a predictor of prognosis and response to immune-checkpoint blockage in metastatic triple-negative invasive breast cancer.2024Asian journal of surgery
  19. PPIH acts as a potential predictive biomarker for patients with common solid tumors.2024BMC cancerFree full text
  20. Interference of the Circular RNA Sperm Antigen With Calponin Homology and Coiled-Coil Domains 1 Suppresses Growth and Promotes Apoptosis of Breast Cancer Cells Partially Through Targeting miR-1236-3p/Chromobox 8 Pathway.2024Clinical breast cancer
  21. TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis.2024Journal of cancer research and clinical oncologyFree full text
  22. Study on the mechanism of heterogeneous tumor-associated macrophages in three subtypes of breast cancer through the integration of single-cell RNA sequencing and in vitro experiments.2024Molecular biology reports
  23. Reproductive Concerns Among Young Adult Women With Breast Cancer: A Systematic Review and Meta-Analysis.2024Psycho-oncology
  24. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.2024The Journal of biological chemistryFree full text
  25. IL-2RG is a predictor of prognosis and response to immune checkpoint blockages and is correlated with immune infiltrates in breast cancer.2023Asian journal of surgery
  26. Reproductive concerns among young adult women with breast cancer: a systematic review protocol.2023BMJ openFree full text
  27. Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway.2023Journal of cellular and molecular medicineFree full text
  28. MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice.2022Anti-cancer agents in medicinal chemistry
  29. Effective diagnostic model construction based on discriminative breast ultrasound image regions using deep feature extraction.2021Medical physics
Chinese-language papers (not in the count)1
  1. [Kaposiform hemangioendothelioma of the breast in an adult female: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status12
  1. Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingNCT07739511Lead (inferred)Phase 1/Phase 2Start 2026-07
  2. Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingNCT07739485Lead (inferred)Phase 1/Phase 2Start 2026-07
  3. A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)RecruitingNCT07876557Study sitePhase 2Start 2026-10
  4. Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Study siteN/AStart 2025-08
  5. Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Study sitePhase 3Start 2025-02
  6. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingNCT06079983Study sitePhase 3Start 2023-12
  7. DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast ReconstructionActive, not recruitingNCT07761390Study siteStart 2026-01
  8. A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerActive, not recruitingNCT06198751Study sitePhase 2Start 2024-02
  9. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  10. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesStatus unknownNCT03500380Study sitePhase 2/Phase 3Start 2018-04
  11. Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in ChinaCompletedNCT03437837Study siteStart 2017-05
  12. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerStatus unknownNCT01642771Study sitePhase 3Start 2012-06

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 21 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.3%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 4420232024: 9920242025: 662025

2 hospitals in Guiyang for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Neurology

Over half of these papers are lab or animal studies.

Papers it led21
  1. Clinical significance of NCOA4 in glioblastoma: diagnostic, prognostic, and therapeutic value.2025BMC cancerFree full text
  2. Expression and prognostic value of ferritinophagy-related NCOA4 gene in low-grade glioma: integration of bioinformatics and experimental validation.2025BMC neurologyFree full text
  3. GABRP Mediates GABA-A Receptor to Shape Tumor Immunosuppressive Microenvironment and Promote Tumor Immune Escape and Corresponding Targeted Therapy.2025Cancer medicineFree full text
  4. USP14-mediated stabilization of ACTN1 maintains mesenchymal characteristics in glioblastoma.2025Communications biologyFree full text
  5. The alternatively spliced diacylglycerol kinase gamma-Δ exon13 transcript generated under hypoxia promotes glioblastoma progression.2025Oncology researchFree full text
  6. ATXN3 deubiquitinates ZEB1 and facilitates epithelial-mesenchymal transition in glioblastoma.2025Scientific reportsFree full text
  7. Daurisoline suppress glioma progression by inhibiting autophagy through PI3K/AKT/mTOR pathway and increases TMZ sensitivity.2024Biochemical pharmacology
  8. EphB3 receptor suppressor invasion, migration and proliferation in glioma by inhibiting EGFR-PI3K/AKT signaling pathway.2024Brain research
  9. Artificial intelligence-based MRI radiomics and radiogenomics in glioma.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  10. Opposite expression of NCOA4 in glioblastoma tissues and cell lines.2024International immunopharmacology
  11. Exploration of the biological mechanisms of CENPA as an oncogene in glioma: Screening based on cancer functional status.2024Journal of cellular and molecular medicineFree full text
  12. Repurposing flubendazole for glioblastoma ferroptosis by affecting xCT and TFRC proteins.2024Journal of cellular and molecular medicineFree full text
  13. NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway.2024Journal of cellular and molecular medicineFree full text
  14. The application value of deep learning in the background of precision medicine in glioblastoma.2024Science progressFree full text
  15. Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study.2024Scientific reportsFree full text
  16. USP10 deubiquitinates RUNX1 and promotes proneural-to-mesenchymal transition in glioblastoma.2023Cell death & diseaseFree full text
  17. A pan-cancer analysis of RGR opsin expression and its downregulation associated with poor prognosis in glioma.2023Neoplasma
  18. Targeting the deubiquitinase USP2 for malignant tumor therapy (Review).2023Oncology reportsFree full text
  19. TPPP3 promote epithelial-mesenchymal transition via Snail1 in glioblastoma.2023Scientific reportsFree full text
  20. Tertiary lymphoid structure stratifies glioma into three distinct tumor subtypes.2021AgingFree full text
  21. Inhibitory effect of gefitinib derivative LPY‑9 on human glioma.2021Molecular medicine reportsFree full text
Chinese-language papers (not in the count)1
  1. [CMTM3 regulates proliferation and migration of glioblastoma U251 cells via the NF-κB signaling pathway].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Guiyang for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Long non-coding RNA XIST confers aggressive progression via miR-361-3p/STX17 in retinoblastoma cells.2020European review for medical and pharmacological sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 332025

6 hospitals in Guiyang for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led8
  1. Primitive Ewing Sarcoma of Epididymis: A Case Report and Literature Review.2025Journal of clinical ultrasound : JCU
  2. 124I-labelled BMSC-Derived Extracellular Vesicles Deliver CRISPR/Cas9 Ribonucleoproteins With a GFP-Reporter System to Inhibit Osteosarcoma Proliferation and Metastasis.2025Journal of extracellular vesiclesFree full text
  3. MMP13 as an effective target of an active trifluoromethyl quinazoline compound against osteosarcoma.2025Toxicology and applied pharmacology
  4. MATN4 as a target gene of HIF-1α promotes the proliferation and metastasis of osteosarcoma.2024AgingFree full text
  5. KCNJ2/HIF1α positive-feedback loop promotes the metastasis of osteosarcoma.2023Cell communication and signaling : CCSFree full text
  6. Hsa_circ_0000073 promotes lipid synthesis of osteosarcoma through hsa-miR-1184/ FADS2 pathway.2023Cellular signalling
  7. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.2022Frontiers in immunologyFree full text
  8. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.2022Technology in cancer research & treatmentFree full text
Earlier papers (2016–2020)3
  1. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis.2019International journal of surgery (London, England)
  2. Correlation between TRAIL and caspase-8 expression and their relationship with cell proliferation and apoptosis in human osteosarcoma.2016Genetics and molecular research : GMR
  3. Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis.2016Journal of orthopaedic surgery and research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Guiyang for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 4 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

3 hospitals in Guiyang for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Guiyang for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Primitive Ewing Sarcoma of Epididymis: A Case Report and Literature Review.2025Journal of clinical ultrasound : JCU

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 4420242025: 222025

2 hospitals in Guiyang for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceStem cell transplant
Departments in papersPediatricsClinical trials / research unit
Papers it led8
  1. Inflammatory Factors and Immune Cells in Relation to Multiple Myeloma.2025Acta haematologica
  2. Effects of mesenchymal stem cells from different sources on the biological functions of multiple myeloma cells.2025Stem cell research & therapyFree full text
  3. RAB22A as a predictor of exosome secretion in the progression and relapse of multiple myeloma.2024AgingFree full text
  4. Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma.2024Annals of hematology
  5. Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma.2024Frontiers in immunologyFree full text
  6. Circulating exosomal miRNA-451 as an effective diagnostic biomarker and prognostic indicator for multiple myeloma.2024The International journal of biological markers
  7. Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma.2022Journal of immunology researchFree full text
  8. C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2.2021Cancer gene therapy
Chinese-language papers (not in the count)1
  1. [Melatonin Induced Apoptosis of RPMI 8226 Cells through Endoplasmic Reticulum Stress].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 112025

1 hospital in Guiyang for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  4. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildrenStem cell transplant

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 7 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 332025

1 hospital in Guiyang for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  3. Recruiting
    Newly-diagnosed Pediatric T-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06855810

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan

  4. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  5. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  6. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine
Papers it led7
  1. ZNF460 enhances HADHB level by activating its transcription to promote the progression and pulmonary invasion of cutaneous T cell lymphoma.2025Archives of biochemistry and biophysics
  2. Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells.2025Journal of translational medicineFree full text
  3. Lenalidomide regulates the CCL21/CCR7/ERK1/2 axis to inhibit migration and proliferation in diffuse large B-cell lymphoma.2025Oncology researchFree full text
  4. Coxsackie B virus-induced myocarditis in a patient with a history of lymphoma: A case report and review of literature.2024MedicineFree full text
  5. Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-cell lymphoma.2023Asia-Pacific journal of clinical oncologyRCT
  6. Remission of extranodal NK/T-cell lymphoma, nasal type, after SARS-CoV-2 vaccination.2023British journal of haematologyFree full text
  7. Development and validation of a nomogram to predict B-cell primary thyroid malignant lymphoma-specific survival: A population-based analysis.2022Frontiers in endocrinologyRCTFree full text
All its trials on ClinicalTrials.gov, any status15
  1. A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Study sitePhase 3Start 2026-03
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Study sitePhase 3Start 2025-01
  3. Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaNot yet recruitingNCT07187960Study sitePhase 3Start 2025-11
  4. Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Study sitePhase 2/Phase 3Start 2025-03
  5. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Study sitePhase 3Start 2023-12
  6. Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT04494503Study sitePhase 1/Phase 2Start 2020-08
  7. A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingNCT05624554Study sitePhase 3Start 2023-03
  8. A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell LymphomaActive, not recruitingNCT05954910Study siteStart 2023-08
  9. Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Study sitePhase 2Start 2022-10
  10. A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04808570Study sitePhase 1/Phase 2Start 2021-06
  11. A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Study sitePhase 3Start 2020-06
  12. A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Study sitePhase 2Start 2019-04
  13. Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma SubjectsCompletedNCT05173545Study sitePhase 1Start 2019-07
  14. Study of GLS-010 Injection in the Treatment of Classical Hodgkin's LymphomaStatus unknownNCT03655483Study sitePhase 2Start 2018-08
  15. A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedNCT03595657Study sitePhase 2Start 2018-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Guiyang for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

1 hospital in Guiyang for haemophilia A132 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Posted
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Posted
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status10
  1. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  2. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  3. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  4. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  5. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  6. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  7. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  8. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Study sitePhase 3Start 2020-03
  9. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  10. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

1 hospital in Guiyang for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyPediatrics
Papers it led3
  1. BMSCs-Derived Extracellular VesiclemiR-29a-3p Improved the Stability of Rat Myasthenia Gravis by Regulating Treg/Th17 Cells.2024Immunological investigations
  2. Nonlinear relationship between circulating natural killer cell count and 1-year relapse rates in myasthenia gravis: a retrospective cohort study.2024PeerJFree full text
  3. Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
Chinese-language papers (not in the count)2
  1. [Detection of memory T cells, follicular T cells and relevant cytokines in the peripheral blood of patients with myasthenia gravis during treatment].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [Two cases of myasthenia gravis with positive anti-acetylcholine receptor antibody and anti-voltage gated calcium channel antibody].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Study sitePhase 1Start 2025-09
  2. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 7 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 2220242025: 112025

2 hospitals in Guiyang for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

2 hospitals in Guiyang for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

3 hospitals in Guiyang for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Guiyang for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Guiyang for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Guiyang for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  2. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Guiyang for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

贵州医科大学附属医院

Affiliated Hospital of Guizhou Medical University

贵阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Guizhou Cancer Hospital; Second Affiliated Hospital of Guizhou Medical University; Guizhou Cancer Center; affiliated hospital of Guizhou medical university; Guizhou Cancer Hospital of Guizhou Medical University

Suggest a correctionDownload the data